Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01166802 · ClinicalTrials.gov registry record

Development of a Questionnaire to Measure Hypervigilance for Visceral Pain

A clinical trial of Irritable Bowel Syndrome, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
157
Enrollment target
1
Study location

NCT01166802 is a study of Irritable Bowel Syndrome that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 157 participants, above the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01166802, a study of Irritable Bowel Syndrome, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
157 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to develop and validate a questionnaire (non-invasive technique) to identify patients who are hypervigilant for noxious visceral sensations and who show a lower threshold to report pain. This questionnaire would be useful in studies investigating the role of visceral pain hypervigilance and pain sensitivity in the comorbidity of IBS with other somatic disorders.

Conditions Studied

Study Locations (1)

North Carolina

  • UNC Center for Clinical and Translational Research - Chapel Hill

Trial Details

FieldValue
Enrollment Target 157 participants
Start Date 2008-02
Est. Completion 2010-06

What the Registry Record Tells You About NCT01166802

The ClinicalTrials.gov registry entry for NCT01166802 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (11% higher). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT01166802 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01166802 about?

NCT01166802 is a clinical study titled "Development of a Questionnaire to Measure Hypervigilance for Visceral Pain". The aim of this study is to develop and validate a questionnaire (non-invasive technique) to identify patients who are hypervigilant for noxious visceral sensations and who show a lower threshold to report pain. This questionnaire would be useful in studies investigating the role of visceral pain hy...

What is the current status of trial NCT01166802?

This trial is currently completed. The enrollment target is 157 participants. The study started on 2008-02. Estimated completion is 2010-06.

What conditions does trial NCT01166802 study?

This clinical trial studies the following conditions: Irritable Bowel Syndrome.

Who is sponsoring clinical trial NCT01166802?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01166802 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Irritable Bowel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.